Randomized Assessment of Rapid Endovascular Treatment in Basilar Artery Occlusion Stroke in 115 Hospital

NCT ID: NCT04177615

Last Updated: 2019-11-26

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

109 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-11-19

Study Completion Date

2020-12-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a prospective, open lable studies conducted in 115 hospital to compare between thromboectomy and Recombinant Tisue Plasminogen Activator only to evaluate the eficacy and safety of endovascular treatment in basilar artery occlusion stroke patients

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Acute basilar artery thrombosis is associated with a poor prognosis. Prevalence of basilar artery occlusion are not known. Although basilar artery occlusion has been reported in 2 per 1000 autopsy cases, basilar artery thrombosis may, in stroke registries, explain as many as 27% of ischemic strokes occurring in the posterior circulation.Various treatments were tried in groups of patients with vertebrobasilar territory infarction but evidence based was not cleared previous studies. Therefore, we conduct this study to evaluate the eficacy and safety of endovascular treatment in basilar artery occlusion stroke patients

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Stroke, Acute Basilar Artery Occlusion

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Thromboectomy and rTPA

use thromboectomy and rtpa for patient with basilar artery occlusion stroke in 24 hour

Group Type EXPERIMENTAL

Thromboectomy

Intervention Type PROCEDURE

Thromboectomy in Basilar Artery Occlusion patients

rTPA( recombinant tissue plasminogen activator )

use rtpa for patient with basilar artery occlusion stroke in 24 hour

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Thromboectomy

Thromboectomy in Basilar Artery Occlusion patients

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients admit to 115 hospital in 24h of Basilar Artery Occlusion Stroke
* NIHSS \> 4 points

Exclusion Criteria

* Patients refuse to participate in studies
* Patients with contraindication of either rTPA or thromboectomy
Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Medicine and Pharmacy at Ho Chi Minh City

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Tran Nguyen Uyen Dung

Randomized Assessment of Rapid Endovascular Treatment in Basilar Artery occlusion stroke in 115 hospital

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

TUAN D Tran, MD

Role: STUDY_CHAIR

UMP university

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

DUNG U Tran Nguyen

Role: CONTACT

0902610832

THANG H Nguyen, MD, PhD

Role: CONTACT

033962478

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

yds2019

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.